U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H48N2O6.2HO
Molecular Weight 686.8336
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METOCURINE HYDROXIDE

SMILES

[OH-].[OH-].[H][C@@]12CC3=CC=C(OC4=C(OC)C(OC)=CC5=C4[C@@]([H])(CC6=CC=C(OC)C(OC7=C(OC)C=C(CC[N+]1(C)C)C2=C7)=C6)[N+](C)(C)CC5)C=C3

InChI

InChIKey=YICFOECHDFPHIN-OIUSMDOTSA-L
InChI=1S/C40H48N2O6.2H2O/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H2/q+2;;/p-2/t31-,32+;;/m0../s1

HIDE SMILES / InChI

Description

Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.

Approval Year

1949
70
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
537
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
METOCURINE IODIDE

Approved Use

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.46 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7023284/
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.05 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7023284/
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7023284/
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7023284/
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1L2HW8
Alfa Chemistry
ACM33335589
BLD Pharm
BD01166218
http://www.bldpharm.com/products/5152-30-7.html
BOC Sciences
7601-55-0
Bosche Scientific
T1675
Compound Cloud
21233
Compound Cloud
24244
NCI Plated 2007
36388
NovoSeek
21233
Specs
AE-562/43459779
Tetrahedron
TS75701
ZINC
ZINC000004097448
http://zinc15.docking.org/substances/ZINC000004097448
eMolecules
260195514
eMolecules
260536772
eMolecules
36726843
PubMed

PubMed

TitleDatePubMed
Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy.
1999 Jan
Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors.
2008 Aug
Reduced blood pressure lability during emergence from anaesthesia in rats: a pilot study using clonidine.
2008 Feb
Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor.
2009 Jan
Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide.
2010
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Name Type Language
METOCURINE HYDROXIDE
Common Name English
TUBOCURARINE, O,O'-DIMETHYL-, DIHYDROXIDE
Common Name English
CHONDROCURARINE, O,O'-DIMETHYL-, DIHYDROXIDE
Common Name English
TUBOCURARANIUM, 6,6',7',12'-TETRAMETHOXY-2,2,2',2'-TETRAMETHYL-, DIHYDROXIDE
Systematic Name English
N,O,O-TRIMETHYLTUBOCURARINE DIHYDROXIDE
Common Name English
O,O-DIMETHYLCHONDROCURARINE DIHYDROXIDE
Common Name English
Code System Code Type Description
CAS
106171-92-0
Created by admin on Fri Dec 15 15:05:31 GMT 2023 , Edited by admin on Fri Dec 15 15:05:31 GMT 2023
PRIMARY
PUBCHEM
72710789
Created by admin on Fri Dec 15 15:05:31 GMT 2023 , Edited by admin on Fri Dec 15 15:05:31 GMT 2023
PRIMARY
FDA UNII
0O224LNG2M
Created by admin on Fri Dec 15 15:05:31 GMT 2023 , Edited by admin on Fri Dec 15 15:05:31 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of METOCURINE
SUBSTANCE RECORD
Structure of METOCURINE HYDROXIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966